AMZNprintsminutestrendsdividendsdrawdownsP/E 28.4macronarrativesvolatilitybuybackssentiment+0.8%marginsMSFTPMI 52.1momentumdividendsflowsPMI 52.1digeststhreadsvolatilityearnings callsvolumesβ 1.24breakoutsnewsflow2s10sliquidityheadlines−1.2%breakoutsnoiseGOOGLbuybacksrevisionstrendsPMI 52.1briefstickersnoiseGDPsentimentchattertranscriptsGOOGLsentimentvolatilitybuybacksMSFTwhispersMETAsessionsyield curves13FfuturesdowngradesPMI 52.1headlinesthe tapeflowsdowngradesfutures+0.8%earnings callstranscriptsclosesgammacatalystsrevisionsvolatilitysentimentchatter+2.41%earnings callssentimentfilingstrends10y 4.21%cyclesbuybackswiresspx 0dtewhisperstickersQ3trendsnewsflowearnings callsWTI 78.2sentimentnoisethreadsrumorsnarrativesFOMCconsensusestimatesmomentumYoY +18%tickersmomentumprintsβ 1.24revisions

momentumheadlines52w hipositioning2s10sfilingstrendsprintstrendsmacrocyclesnoise2s10smacroQ3narrativesheadlinesflowscyclesnarrativesspreadstranscriptsdowngradesupgradeswhisperswhispersminutesthe tapeNDXfuturesminutesyield curves52w hithe tapeFOMCcatalystsbriefsthe tapeNVDAguidancetrends52w hidrawdowns2s10swhispersmomentumdrawdownsbuybacks

PCEliquiditysentimentbreakoutsdowngradesP/E 28.4threadsAAPLSPXvolatilityNDXflowscyclesliquidityestimatesEPS 4.12

BCRX · NASDAQ · Biotechnology

BioCryst Pharmaceuticals (BCRX)

Commercializes oral ORLADEYO and develops injectable navenibart for hereditary angioedema.

$8.75

After hours−0.02 (−0.23%)

At close$8.77(+0.11%)

In millions of USD, except per-share figures

In millions	Q3 FY23Sep 2023	Q4 FY23Dec 2023	Q1 FY24Mar 2024	Q2 FY24Jun 2024	Q3 FY24Sep 2024	Q4 FY24Dec 2024	Q1 FY25Mar 2025	Q2 FY25Jun 2025	Q3 FY25Sep 2025	Q4 FY25Dec 2025	Q1 FY26Mar 2026	Q2 FY26Jun 2026
Revenue	87	93	93	109	117	132	146	163	159	407	156	218
Cost of revenue	1	2	1	2	3	6	5	3	3	10	703	4
Gross profit	86	92	91	108	114	125	141	161	157	397	−547	214
	98	134	106	99	106	130	120	131	127	137	155	116
Research & development	47	70	46	38	41	49	37	43	44	41	60	52
	51	64	59	61	65	80	82	87	83	96	95	64
General & administrative	0	0	0	0	0	0	0	0	0	0	0	64
Other expenses	0	0	0	0	0	0	0	0	0	0	0	0
Operating income	−12	−43	−14	9	8	−5	21	30	30	260	−702	98
	−24	−20	−21	−21	−21	−21	−20	−23	−17	−12	−19	−19
Interest income	4	4	4	4	4	4	3	3	2	3	2	2
Interest expense	27	25	25	25	25	24	23	22	20	14	20	22
Other non-operating income	−3	−4	−4	−3	−4	−3	−3	2	−2	−2	−1	0
Income before tax	−36	−63	−35	−13	−13	−26	1	6	12	248	−721	79
Income tax expense	0	−1	0	0	1	1	1	1	−1	2	1	1
Net income from continuing operations	−36	−62	−35	−13	−14	−27	0	5	13	246	−722	78
Net income	−36	−62	−35	−13	−14	−27	0	5	13	246	−722	78
EPS, basic	−$0.19	−$0.31	−$0.17	−$0.06	−$0.07	−$0.13	$0.00	$0.02	$0.06	$1.17	−$2.98	$0.31
EPS, diluted	−$0.19	−$0.31	−$0.17	−$0.06	−$0.07	−$0.13	$0.00	$0.02	$0.06	$1.12	−$2.98	$0.30
Weighted average shares, basic	190	201	206	206	207	207	209	210	210	211	242	254
Weighted average shares, diluted	190	201	206	206	207	207	215	220	220	219	242	265
EBITDA	−8	−38	−10	13	12	−1	25	28	32	266	−700	99
Depreciation & amortization	0	0	0	0	0	0	0	0	0	4	1	1
EBIT	−8	−39	−11	12	11	−2	24	28	32	262	−701	98